Article

QEEG guided neurofeedback therapy in personality disorders: 13 case studies

Living Health Center for Research and Education, Gazeteciler Mah. Saglam Fikir Sokak. No: 17 Esentepe, Sisli, Istanbul 34387, Turkey.
Clinical EEG and neuroscience: official journal of the EEG and Clinical Neuroscience Society (ENCS) (Impact Factor: 3.16). 02/2009; 40(1):5-10. DOI: 10.1177/155005940904000107
Source: PubMed

ABSTRACT According to DSM-IV, personality disorder constitutes a class only when personality traits are inflexible and maladaptive and cause either significant functional impairment or subjective distress. Classical treatment of choice for personality disorders has been psychotherapy and/or psychopharmacotherapy. Our study is to determine if subjects with antisocial personality disorders will benefit from quantitative EEG (qEEG) guided neurofeedback treatment. Thirteen subjects (9 male, 4 female) ranged in age from 19 to 48 years. All the subjects were free of medications and illicit drugs. We excluded subjects with other mental disorders by clinical assessment. Psychotherapy or psychopharmacotherapy or any other treatment model was not introduced to any of the subjects during or after neurofeedback treatment. For the subject who did not respond to neurofeedback, training was applied with 38 sessions of LORETA neurofeedback training without success. Evaluation measures included qEEG analysis with Nx Link data base, MMPI, T.O.V.A tests and SA-45 questionaries at baseline, and at the end of neurofeedback treatment. Lexicor qEEG signals were sampled at 128 Hz with 30 minutes-neurofeedback sessions completed between 80-120 sessions depending on the case, by Biolex neurofeedback system. At baseline and after every 20 sessions, patients were recorded with webcam during the interview. Twelve out of 13 subjects who received 80-120 sessions of neurofeedback training showed significant improvement based on SA-45 questionaries, MMPI, T.O.V.A. and qEEG/Nx Link data base (Neurometric analysis) results, and interviewing by parent/family members. Neurofeedback can change the view of psychiatrists and psychologists in the future regarding the treatment of personality disorders. This study provides the first evidence for positive effects of neurofeedback treatment in antisocial personality disorders. Further study with controls is warranted.

Download full-text

Full-text

Available from: Tanju Surmeli, Jan 14, 2015
5 Followers
 · 
353 Views
  • Source
    • "Smith and Sams (2005) showed improvements in attention and behavior in a group of juvenile offenders, and a study in a Boys Totem Town project with seven juvenile felons (Martin & Johnson, 2005) improvements were noted on a variety of measures. Most recently, Surmeli and Ertem (2009) presented a case series of 13 patients who received from 80 to 100 neurofeedback treatment sessions guided by QEEG findings. Outcomes were measured with the Minnesota Multiphasic Personality Inventory, a test of attention, QEEG results, and interviews with family members. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Written to educate both professionals and the general public, this article provides an update and overview of the field of neurofeedback (EEG biofeedback). The process of assessment and neurofeedback training is explained. Then, areas in which neurofeedback is being used as a treatment are identified and a survey of research findings is presented. Potential risks, side effects, and adverse reactions are cited and guidelines provided for selecting a legitimately qualified practitioner.
    Journal of Neurotherapy 10/2011; 15(4):305-336. DOI:10.1080/10874208.2011.623090
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Affective Brain-Computer Interfaces (BCI) are systems that measure signals from the peripheral and central nervous system, extract features related to affective states of the user, and use these features to adapt human-computer interaction (HCI). Affective BCIs provide new perspectives on the applicability of BCIs. Affective BCIs may serve as assessment tools and adaptive systems for HCI for the general population and may prove to be especially interesting for people with severe motor impairment. In this context, affective BCIs will enable simultaneous expression of affect and content, thus providing more quality of life for the patient and the caregiver. In the present paper, we will present psychophysiological markers for affective BCIs, and discuss their usability in the day to day life of patients with amyotrophic lateral sclerosis (ALS).
    Affective Computing and Intelligent Interaction and Workshops, 2009. ACII 2009. 3rd International Conference on; 10/2009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is sometimes considered one of the most devastating of mental illnesses because its onset is early in a patient's life and its symptoms can be destructive to the patient, the family, and friends. Schizophrenia affects 1 in 100 people at some point during their lives, and while there is no cure, it is treatable with antipsychotic medications. According to the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE), about 74% of the patients who have discontinued the first medication prescribed within a year will have a relapse afterward. This shows an enormous need for developing better treatment methods and better ways to manage the disease, since current therapies do not have sufficient impact on negative symptoms, cognitive dysfunction, and compliance to treatment. In this clinical case series, we investigate the efficacy of quantitative electroencephalography (qEEG)-guided neurofeedback (NF) treatment in this population, and whether this method has an effect on concurrent medical treatment and on the patients. Fifty-one participants (25 males and 26 females) ranging from 17 to 54 years of age (mean: 28.82 years and SD: 7.94 years) were included. Signed consent was received from all patients. Most of the participants were previously diagnosed with chronic schizophrenia, and their symptoms did not improve with medication. All 51 patients were evaluated using qEEG, which was recorded at baseline and following treatment. Before recording the qEEG, participants were washed out for up to 7 half-lives of the medication. After Food and Drug Administration (FDA)-approved Nx-Link Neurometric analysis, qEEGs suggested a diagnosis of chronic schizophrenia for all participants. This was consistent with the clinical judgment of the authors. The participants' symptoms were assessed by means of the Positive and Negative Syndrome Scale (PANSS). Besides the PANSS, 33 out of 51 participants were also evaluated by the Minnesota Multiphasic Personality Inventory (MMPI) and the Test of Variables of Attention (TOVA), both at baseline and following treatment. Each participant was prescribed an NF treatment protocol based on the results of their qEEG neurometric analysis. Each session was 60 minutes in duration, with 1 to 2 sessions per day. When 2 sessions were administered during a single day, a 30-minute rest was given between the sessions. Changes in the PANSS, MMPI, and TOVA were analyzed to evaluate the effectiveness of NF treatment. The mean number of sessions completed by the participants was 58.5 sessions within 24 to 91 days. Three dropped out of treatment between 30 and 40 sessions of NF, and one did not show any response. Of the remaining 48 participants 47 showed clinical improvement after NF treatment, based on changes in their PANSS scores. The participants who were able to take the MMPI and the TOVA showed significant improvements in these measures as well. Forty were followed up for more than 22 months, 2 for 1 year, 1 for 9 months, and 3 for between 1 and 3 months after completion of NF. Overall NF was shown to be effective. This study provides the first evidence for positive effects of NF in schizophrenia.
    Clinical EEG and neuroscience: official journal of the EEG and Clinical Neuroscience Society (ENCS) 03/2012; 43(2):133-44. DOI:10.1177/1550059411429531 · 3.16 Impact Factor
Show more